Two news threads that started with relatively isolated moves are showing signs of becoming trends, with word that Beijing is taking new actions against overseas tech and drug firms. In the former case, media are reporting that China is preparing to roll out new security checks for all foreign IT products, in a move that looks aimed at the computing and telecoms sectors. The latter case has media reporting that investigators have visited the offices of Swiss drug giant Roche (Switzerland: ROG), which could auger more formal moves against the company for corrupt business practices. Read Full Post…
After several months of silence as they were targeted for a series of anti-graft investigations, I’m happy to see that western firms are finally speaking out about the biased nature of this Chinese campaign against them. The firms are voicing their grievance through an industry organization, the European Union Chamber of Commerce, which is complaining that western drug makers have been unfairly targeted in the campaign that began around 2 months ago and has netted such big names as Britain’s GlaxoSmithKline (GSK) (London: GSK), Switzerland’s Novartis (Switzerland: NOVN) and French drug maker Sanofi (SAN). At the same time, the United Nations is adding its voice to the debate, saying this kind of anti-corruption campaign should be a welcome step to cleaning up the country’s business environment. Read Full Post…
Lilly joins list of drug makers accused of massive bribery
I thought that maybe I had accidentally opened an old news page today when I read the latest headline that US drug maker Eli Lilly (NYSE: LLY) had been accused of massive bribery in China to sell its medicines. In fact, the headline wasn’t even directly about the allegations that had come from a Chinese newspaper report, but was rather based on a Lilly executive who commented that the company was “deeply concerned” about the latest claims that it spent more than 30 million yuan ($4.8 million) to bribe Chinese doctors to use its medicines. (English article) Read Full Post…
China has embarked on a recent campaign to clean up its drug sector of aggressive selling tactics that often include bribing doctors and hospital officials to boost sales. The choice of the drug firms looks smart, as it takes aim at a rapidly transforming Chinese medical sector where many business practices are still in their formative stages. More broadly speaking, this kind of campaign also sends a strong signal that Beijing won’t tolerate the kind of bribery and other aggressive and often unethical business practices that have become far too common in many Chinese industries. Read Full Post…
Beijing is returning to a time-tested tactic from its PR playbook with a sudden flurry of high-profile probes of major multinationals, which are being accused of everything from price manipulation to bribery. This latest series of “scandals” has snared some of the most active foreign firms in China, including pharmaceutical giant GlaxoSmithKline, milk powder maker Mead Johnson and packaging products titan Tetra Pak. Read Full Post…
China’s state planner has always been a potent force in making big investment decisions that affect the macro economy, and now it’s quickly emerging as a potent regulator of product pricing by the private sector. That’s my major conclusion following news for the second time this week that the National Development and Reform Commission (NDRC) is conducting yet another pricing investigation against foreign firms it suspects of fixing prices artificially high. Earlier this week the target of a new probe was foreign milk powder makers, and this time it’s foreign drug makers including Merck (NYSE: MRK), GlaxoSmithKline (London: GSK), Novartis (Switzerlan; NOVN) and around 2 dozen other companies. Read Full Post…
